Investigators conducted this phase III trial to determine whether immunotherapy was more effective when administered early in the day.
More than 30 million people with HIV must take antiretroviral therapy (ART) medications daily to keep the virus under control ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results